Therapeutic Use of Truncated Plasmin
Symptomatic vitreomacular adhesion (VMA) is a vision-threatening condition when the vitreous gel adheres unusually tightly to the retina, which leads to a variety of retinal abnormalities.
As non-specific serine protease, plasmin or truncated plasmin have been developed as nonsurgical enzyme therapeutics for treating symptomatic VMA. Plasmin directly or indirectly regulates the fibrinolysis and lysis of a variety of vitreous macromolecules. This approach can enable the proteolytic degradation of protein components (‘glue’ molecules) of the vitreous body and the vitreoretinal interface (e.g. laminin, fibronectin, and collagen) caused by VMA.
Ocriplasmin, also known as Jetrea or microplasmin, is a shortened recombinant form of human serine protease plasmin that is produced in an expression system in Pichia pastoris. It is composed of two peptide chains, each containing 19 and 230 amino acids, and has a molecular weight of 27.2 kDa.Ocriplasmin is developed for treating symptomatic VMA through selectively cleaving the peptide bonds at the C-termini of arginine (Arg) or lysine (Lys) residues.
Ocriplasmin (Jetrea) is now available in the US (FDA) and Europe (EMA). It is developed and commercialized by Oxurion (formerly ThromboGenics). In 2020, Inceptua obtained the global commercial rights to Jetrea from Oxurion NV.
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Truncated Plasmin
Truncated Plasmin Pipeline
Generic Name
|
Brand Name/ Alternative Name
|
Expression System
|
Indications
|
Manufacturer
|
R&D Stage
|
Ocriplasmin
|
Jejetrea, THR-409, A-01016, Jetrea
|
Yeast (Pichia pastoris)
|
Retinal disorders, Symptomatic vitreomacular adhesions, Diabetic retinopathy
|
Thrombogenics, Inc., Oxurion NV, Alcon AG
|
Approved
|
JZB-32
|
Recombinant human truncated plasmin
|
Pending update
|
Symptomatic vitreomacular adhesions, Polyp-like choroidal vascular disease
|
Chengdu Zeyan Biotechnology, Hefei Zeyan Biotechnology
|
Phase I
|
Ocriplasmin
|
GW005, Recombinant truncated human plasmin
|
Yeast
|
Symptomatic vitreomacular adhesions
|
Mabwell Bioscience
|
Pre-clinical
|